Symphogen, a Danish biopharmaceutical company developing antibody therapeutics, has appointed Dr. Ivan D. Horak as its new chief scientific/medical officer. Dr. Horak joins Symphogen from Enzon, where he was chief scientific officer for six years. He has also held several senior research leadership positions at organisations such as Immunomedics and Pharmacia & Upjohn.
Symphogen has also appointed Gayle M. Mills as its new chief business officer. Ms Mills joins Symphogen from Californian pharmaceutical company Roxro Pharma, Inc., where she has been EVP of business operations and chief business officer for the last five years.